CRISPR Therapeutics Newsroom

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Zacks Nov 20 21:35

Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsNov 20 20:33 · Ratings

CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now

Yahoo FinanceNov 20 08:03

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Earnings Call TranscriptsNov 16 00:37

Gilead, Vertex Initiated as New Big Biotech Buys at Citi

Seeking AlphaNov 15 03:26

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 13 03:21

Form 144 | CRISPR Therapeutics(CRSP.US) Officer Proposes to Sell 4.11 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Nov 12, $CRISPR Therapeutics(CRSP.US)$ Officer Dr. Samarth Kulkarni intends to sell 75,000 shares of its common stock on Nov 11, with a total market value of approximately $4.1

Futu NewsNov 13 02:13

Cathie Wood's ARK Innovation ETF Is a Trump Trade Winner as Tesla Soars. But It Still Lags the Market.

BarronsNov 13 00:38

Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy

PR NewswireNov 12 20:45

Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu NewsNov 12 16:33 · Ratings

Positive Outlook on Crispr Therapeutics AG Driven by Strong Pricing and Strategic Partnerships

TipRanksNov 12 15:47

CRISPR, Beam, Other Gene Editing Names up Significantly

Seeking AlphaNov 12 02:15

Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45

Futu NewsNov 8 22:38 · Ratings

A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95

Futu NewsNov 7 21:00 · Ratings

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

GlobeNewswireNov 7 21:00

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Yahoo FinanceNov 7 20:42

CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com

BusinesswireNov 7 01:21

RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target

BenzingaNov 7 00:18 · Ratings

A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94

Futu NewsNov 6 21:00 · Ratings

Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TipRanksNov 6 20:58 · Ratings